Carisbamate
- Generic Name
- Carisbamate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H10ClNO3
- CAS Number
- 194085-75-1
- Unique Ingredient Identifier
- P7725I9V3Z
- Background
Carisbamate has been investigated in Alcohol Abuse, Substance Abuse, and Alcohol Dependence.
- Associated Conditions
- -
- Associated Therapies
- -
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT05219617
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇮🇱Soroka University Medical Centre, Be'er Sheva, Israel
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Bioavailability and Food Effect Study of 3 Types of Carisbamate
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT04520360
- Locations
- 🇺🇸
PRA Health Sciences- Salt Lake City, Salt Lake City, Utah, United States
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04062981
- Locations
- 🇺🇸
UW Valley Medical Center, Renton, Washington, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03731715
- Locations
- 🇺🇸
Duke Health, Durham, North Carolina, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸UW Valley Medical Center, Renton, Washington, United States
Carisbamate as a Potential Treatment for Alcohol Dependence
- Conditions
- Interventions
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT02435381
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.
- Conditions
- Interventions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 991
- Registration Number
- NCT00991757
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
- Conditions
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT00744731
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
- Conditions
- Interventions
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 547
- Registration Number
- NCT00740623
Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.
- Conditions
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT00563459
A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
- Conditions
- Interventions
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00524056
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.